Dasatinib good news in chronic-phase CML

By  

Inpharma, Vol. 1, Iss. 1619, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Predicting early blast transformation in chronic-phase chronic myeloid leukemia: Is immunophenotyping the missing link?

By El Rassi Fuad   Bergsagel John D.   Arellano Martha   Gaddh Manila   Jillella Anand   Kota Vamsi   Heffner Leonard T.   Winton Elliott F.   Khoury Hanna Jean  

Cancer, Vol. 121, Iss. 6, 2015-03 ,pp. : 872-875

Blackwell Publishing

Access to resources Recommend Favorite

Identification of heptapeptides interacting with IFN-α-sensitive CML cells

By Liu Jia   Chen Han-chun   Rao Zhou-zhou   Khan Md. Asaduzzaman   Wan Xin-xing   Xu Ai-hua   Zhang Nuo   Zhang Dian-zheng  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 12, 2011-12 ,pp. : 1583-1589

Informa Healthcare

Access to resources Recommend Favorite

Advances in Immunotherapy of Chronic Myeloid Leukemia CML

By  

Current Cancer Drug Targets, Vol. 13, Iss. 7, 2013-09 ,pp. : 768-774

Bentham Science Publishers

Access to resources Recommend Favorite

Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-α Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia

By Reed Shelby D.   Anstrom Kevin J.   Li Yanhong   Schulman Kevin A.  

PharmacoEconomics, Vol. 26, Iss. 5, 2008-01 ,pp. : 435-446

Adis International

Access to resources Recommend Favorite